Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Zwitserland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Nieuws
  7. Persberichten
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Rapport
Vertraagde tijd Swiss Exchange  -  17:31 05-10-2022
504.80 CHF   -1.10%
27/09Lonza Group AG : AlphaValue herhaalt koopadvies voor het aandeel
MM
15/09Lonza vergroot de capaciteit van de Zwitserse vestiging om antilichaam-drugsconjugaten te produceren
MT
12/09Lonza benoemt Daniel Palmacci tot President van de Cell & Gene Divisie, met ingang van 1 november 2022
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société LONZA GROUP AG
12/09Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
EQ
06/09Lonza and Touchlight collaborate on end-to-end mRNA offering
EQ
28/07Lonza : Half-Year Alternative Performance Measures Report
PU
22/07Lonza : Half-Year Results Report
PU
22/07Lonza : Half-Year Results Presentation
PU
22/07Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE ..
EQ
01/07Maria Soler Nunez appointed as Head, Group Operations
EQ
01/07Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein..
EQ
24/06Lonza : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bior..
PU
07/06Lonza : More Sensitive Non-endotoxin Pyrogen Detection Now Possible with Lonza's New PyroC..
PU
01/06Lonza : Completes Dedicated Early Clinical Phase Development and Manufacturing Facility in..
PU
25/05Lonza and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics an..
AQ
24/05Lonza : and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics and..
PU
23/05Lonza : to Expand Inhalation Capabilities at Tampa Site
PU
29/04Lonza : to Divest its Quakertown Site Specialized in Particle Size Reduction; Business to ..
PU
26/04Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using ..
AQ
25/04Lonza : Early Development Services and Integral Molecular to Offer Complementary Expertise..
PU
25/04Lonza : Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody u..
PU
07/04Lonza : and Asher Biotherapeutics to Collaborate on Manufacturing AB359, a Cis-Targeted IL..
PU
04/04Lonza : Expands the Functionality of Cocoon Platform by Implementing Magnetic Cell Selecti..
PU
31/03Lonza : Joins IPAC-RS, an International Consortium Advancing the Regulatory Science of Inh..
PU
24/03Lonza : Publishes Invitation to the 2022 Annual General Meeting and 2021 Annual and Sustai..
PU
23/03Lonza Group - Christian Seufert appointed as President of Capsules and Health Ingredien..
AQ
23/03Lonza : Christian Seufert appointed as President of Capsules and Health Ingredients Divisi..
PU
21/03Lonza : Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate ..
PU
15/03Lonza : is among the 2022 World's Most Ethical Companies, as recognized by Ethisphere
PU
08/03Lonza : Expands API Development and Manufacturing Laboratories in Nansha, China
PU
07/03Lonza : Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mous..
PU
27/01HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candi..
PR
26/01Lonza : Full-Year Alternative Performance Measures Report
PU
26/01Lonza : Full-Year Results Report
PU
26/01Lonza : Full-Year Results Presentation
PU
26/01Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
EQ
25/01Lonza : Obtains Order Preventing Infringement of Its Patents Covering the Cocoon® Platform
PU
19/01Lonza : Drug Product Services Participates in the RealHOPE Project to Assess and Improve P..
PU
18/01Lonza : Forbion, and BioGeneration Ventures Extend Collaboration to Add Development and Ma..
PU
18/01Lonza : Launches bYlok Technology for the Discovery and Design of Bispecific Antibodies
PU
2021Lonza and Agilent Announce Strategic Collaboration to Integrate New Analytical Technolo..
AQ
2021Lonza : and Agilent Announce Strategic Collaboration to Integrate New Analytical Technolog..
PU
2021Lonza : Doer Biologics signs licensing agreement with Lonza to develop multi-specific biot..
PU
2021Lonza : and Bioqube Ventures Sign a Framework Agreement for the Future Development and Man..
PU
2021Lonza : and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778..
PU
2021Lonza : to Expand Microbial Development Laboratories
PU
2021Lonza to Acquire Exosomics Service Unit to Expand Exosomes Service Offering
PU
2021Lonza : to Expand Development Services for Mammalian Products in Singapore
PU
2021Lonza : Invests to Expand Drug Product Development and Manufacturing Services in Switzerla..
PU
2021Lonza : Philippe Deecke appointed as Chief Financial Officer of Lonza Group
PU
2021Lonza : and Sheba Medical Center Use Cocoon Platform and Show Successful Clinical Outcomes..
AQ
2021Lonza : and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcome..
PU
2021Lonza : Half-Year Alternative Performance Measures Report
PU
2021Lonza : Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBI..
PU
2021Lonza : and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for ..
PU
2021Lonza : Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclo..
PU
2021Lonza : Completes Divestment of Specialty Ingredients Business
AQ
2021Lonza : Completes Divestment of Specialty Ingredients Business
EQ
2021Lonza : Kaged Muscle First to Launch with Lonza's TWK10® Sports Probiotic in the USA
PU
2021Lonza : Restated Financials News Release English
PU
2021General Announcement : :Lonza Publishes Restated Financials for 2020
PU
2021Lonza : Publishes Restated Financials for 2020
EQ
2021Lonza : Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nan..
PU
2021Lonza : Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Ant..
PU
2021Lonza : CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeutics Manufa..
PU
2021Lonza : Headline
PU
2021Lonza : SelectImmune Collaborates with Lonza to Develop an Immunotherapeutic Drug Candidat..
PU
2021Lonza : SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherapeutic Drug C..
AQ
2021Lonza : and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421, an anti-IGF..
PU
2021Moderna : Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturin..
AQ
2021Lonza : and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COV..
PU
2021Lonza : and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COV..
EQ
2021Lonza : Launches Next Generation 4D-Nucleofector Cell Transfection Platform with Proven Pe..
PU
2021Lonza : Launches Next Gene…nd Enhanced Ease of Use
PU
2021Lonza : Announces Results of the 2021 Annual General Meeting - All Motions Proposed by Boa..
AQ
2021Lonza : Price Change Notification on Selected Product Portfolios
PU
2021Lonza : Announces Results of the 2021 Annual General Meeting – All Motions Proposed ..
PU
2021Lonza : Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities i..
PU
1  2  3  4  5  6  7  8Volgende
Volgende evenement op LONZA GROUP AG